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Pimvastatin Attenuates Plaque Inflammation
valuation by Fluorodeoxyglucose Positron Emission Tomography
obuhiro Tahara, MD, PHD,* Hisashi Kai, MD, PHD,* Masatoshi Ishibashi, MD, PHD,†
iroyuki Nakaura, MD, PHD,* Hayato Kaida, MD,† Kenkichi Baba, MD,†
aofumi Hayabuchi, MD, PHD,† Tsutomu Imaizumi, MD, PHD*
urume, Japan
OBJECTIVES We investigated whether simvastatin attenuates plaque inflammation by using 18F-
fluorodeoxyglucose positron emission tomography (18FDG-PET) co-registered with com-
puterized tomography.
BACKGROUND Inflammation plays a key role in progression and destabilization of atherosclerotic plaque.
18F-fluorodeoxyglucose PET is a promising tool for visualizing inflammation of atheroscle-
rotic plaque. Antiinflammatory action is one of the pleiotropic effects of statins.
METHODS Forty-three consecutive subjects, who underwent 18FDG-PET for cancer screening and had
18FDG uptakes in the thoracic aorta and/or the carotid arteries, were randomized to either
statin group receiving simvastatin (n  21) or diet group receiving dietary management only
(n  22). The maximum standardized uptake values (SUVs) were measured in individual
plaques, and were averaged for analysis of the subjectwise results. The responses were assessed
after 3-month treatments.
RESULTS Positron emission tomography revealed 117 and 123 18FDG-positive plaques in the statin
and diet groups, respectively. Simvastatin, but not diet alone, attenuated plaque 18FDG
uptakes and decreased the SUVs (p  0.01). Simvastatin reduced low-density lipoprotein
cholesterol (LDL-C) by 30% (p  0.01) and increased high-density lipoprotein cholesterol
(HDL-C) by 15% (p  0.01), whereas LDL-C and HDL-C levels were not changed in the
diet group. In the statin group, the decrease in the SUV was well correlated with the HDL-C
elevation (p  0.01) but not with the LDL-C reduction.
CONCLUSIONS 18F-fluorodeoxyglucose PET visualized plaque inflammation and simvastatin attenuated it.
The LDL-C–independent effects of simvastatin may participate in the beneficial effect.
18F-fluorodeoxyglucose PET has a potential for visually monitoring plaque inflammation and
the therapeutic effectiveness of statins. (J Am Coll Cardiol 2006;48:1825–31) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.069the American College of Cardiology Foundation
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atherosclerosis is now widely accepted as a chronic vascular
nflammatory disorder. Inflammation mediates various stages
f atheroma development and progression from initial leuko-
yte recruitment to eventual rupture of the vulnerable plaque
1). Because of the singular properties of 18F-fluoro-
eoxyglucose (18FDG), a synthetic tracer that mimics the
iochemical behavior of the natural glucose molecule,
8FDG positron emission tomography (18FDG-PET) has
een established to be useful for detecting not only tumor
ells but also inflammatory cells (2). Earlier retrospective
tudies reported that 18FDG accumulation was incidentally
etected in the aorta and the iliac and femoral arteries in
0% to 50% of patients who had undergone 18FDG-PET
or various clinical indications (3–5). Recently, Rudd et al.
6) have shown that 18FDG accumulation corresponds to the
acrophage-rich area of the plaque, which was endoatherec-
omized from 18FDG-PET–positive carotid lesions. These
bservations suggested that 18FDG-PET imaging is capable of
isualizing atherosclerotic plaque inflammation.
From the *Department of Medicine/Cardiovascular Research Institute, Division of
ardio-Vascular Medicine, and †Department of Radiology, Kurume University
chool of Medicine, Kurume, Japan. Supported in part by a research grant from the
imura Memorial Foundation and by a grant for the Academic Frontier Project from
he Ministry of Education, Science, Sports, Culture, and Technology, Japan.s
Manuscript received January 10, 2006; revised manuscript received March 3, 2006,
ccepted March 6, 2006.Lipid-lowering therapy with statins significantly de-
reases cardiovascular morbidity and mortality in primary
nd secondary prevention (7,8). Statins exert their benefits
hrough the inhibition of de novo cholesterol synthesis,
esulting in significant reductions in plasma low-density
ipoprotein cholesterol (LDL-C) levels. It remains contro-
ersial whether LDL-C lowering is the only mechanism for
he observed beneficial effects. Many LDL-C–independent
leiotropic effects have been postulated. One of them is
ttenuation of inflammation because statins have been
hown to decrease systemic inflammatory markers (9,10).
owever, no visual evidence that statins attenuate plaque
nflammation has been documented noninvasively in clinical
ractice. 18F-fluorodeoxyglucose PET may provide nonin-
asive longitudinal evaluation of plaque inflammation after
tatin therapy. Accordingly, in the present study, we inves-
igated by serial 18FDG-PET imaging whether simvastatin
educed inflammation of the plaques.
ETHODS
esign and subjects. This study was a prospective, ran-
omized, controlled study involving 3 months of study: drug
dministration and follow-up. The study protocol was
pproved by the Ethics Committee for the Clinical Re-
earch of Kurume University. All subjects gave written
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Statin Reduces Plaque Inflammation November 7, 2006:1825–31nformed consent. The study included 43 consecutive sub-
ects in whom 18FDG-PET imaging for voluntary cancer
creening revealed incidental 18FDG uptakes in the thoracic
orta and/or the carotid arteries, including the innominate
nd the common carotid arteries and the extracranial seg-
ents of the internal and external carotid arteries. This
tudy excluded subjects with active inflammatory diseases,
yslipidemia under medications, vasculitis, symptomatic
oronary artery disease, symptomatic cerebrovascular dis-
ases, and known systemic disorders such as hepatic, renal,
ematologic, and malignant diseases.
reatment. The study subjects were randomized to either
iet group receiving dietary management (n  22) or statin
roup receiving simvastatin in addition to dietary manage-
ent (n  21). Dietary management was performed ac-
ording to the Japan Atherosclerosis Society Guidelines for
iagnosis and Treatment of Atherosclerotic Cardiovascular
iseases (11). In the statin group, the starting dose of
imvastatin was 5 or 10 mg/day. When LDL-C level was
ore than 130 mg/dl (3.4 mmol/l) after 1 month of
reatment, the dose of simvastatin was increased to 20
g/day, the approved maximum dose in Japan. Conse-
uently, the maintenance dose of simvastatin was 5 mg/day
or 2 subjects, 10 mg/day for 14 subjects, and 20 mg/day for
subjects.
8FDG PET imaging. After at least 12 h of fasting, the
tudy subjects received an intravenous administration of 4.2
Bq (0.11 mCi)/kg of 18FDG. One hour after 18FDG
njection, 3-dimensional whole-body PET imaging was
arried out using a PET scanner (Allegro, Philips Medical
ystems [Cleveland], Inc., Cleveland, Ohio), which uses
adolinium oxyorthosilicate as the detector material.
ontrast-enhanced computed tomographic (CT) images
ere also taken from the skull base to the diaphragm using
ight Speed Ultra 16 (GE Healthcare, Milwaukee, Wis-
onsin). The co-registration of PET and CT images (soft-
are image fusion) was performed for review on a worksta-
ion (Sun Microsystems, Inc., Santa Clara, California) as
escribed previously (6).
The 18FDG-PET images were visually evaluated for
he presence of abnormal 18FDG uptakes in the aorta and
he carotid arteries on the basis of the agreement of 3
adiologists specializing in nuclear medicine blinded to
ther clinical information and treatment assignments.
rterial uptake of 18FDG was validated when co-
Abbreviations and Acronyms
18FDG  18F-fluorodeoxyglucose
CT  computed tomography
HDL-C  high-density lipoprotein cholesterol
hsCRP  high-sensitivity C-reactive protein
LDL-C  low-density lipoprotein cholesterol
MRI  magnetic resonance imaging
PET  positron emission tomographyegistration of PET and CT showed that the accumula- rion overlapped on the vascular wall. The intensity of
8FDG uptake was quantified by determining the stan-
ardized uptake value (SUV) corrected for lean body
ass. A region of interest was placed on the transaxial
mage to totally surround the most intense area of the
8FDG uptake, and the SUV was calculated by using the
aximum pixel activity value within the region of inter-
st. Special attention was given to match PET images of
he same patient at baseline and at follow-up by measur-
ng the distance from the carotid bifurcation for the
arotid lesions or the distance from the top of the aortic
rch for the aortic lesions, assessed by co-registered CT
mages. Two radiologists measured the SUV, and the
easurements were averaged in each plaque. The intra-
nd interobserver variabilities of SUV measurements
ere 5%. If multiple abnormal areas of 18FDG uptake
ere found in 1 vessel segment, and if they were each
learly distinguishable from one another, they were re-
orded separately. In individual plaques, the changes in
he SUV (SUV) were calculated by subtracting the SUV
t baseline from the SUV after 3-month treatment. The
ubjectwise SUV and SUV were calculated by averaging
he plaquewise SUVs and SUVs, respectively, in each
ubject.
ipids and inflammatory markers. On the day of PET
tudy, after overnight fasting, peripheral blood was drawn
rom the antecubital vein for the measurements of LDL-C,
igh-density lipoprotein cholesterol (HDL-C), triglycerides,
able 1. Baseline Demographics
Diet Group
(n  22)
Statin Group
(n  21)
ge, yrs (range) 62  6 (47–72) 65  9 (45–77)
ale/female, n 14/8 13/8
ody mass index, kg/m2 22.8  2.0 23.6  3.3
ystolic blood pressure, mm Hg 134  14 130  16
ulse pressure, mm Hg 54  10 54  13
lasma glucose, mg/dl 106  14 102  13
emoglobin A1c, % 5.5  0.4 5.7  0.8
VD risk factor, n
Current smoking 3 2
Former smoking 12 10
Hypertension 14 11
Hypercholesterolemia 10 9
Hypertriglycemia 9 8
Diabetes mellitus 3 4
History of cardiovascular diseases 2 3
edications, n
Aspirin 6 8
Antihypertensives 8 10
ARB or ACEI 5 7
Oral antidiabetics 2 2
ypertension was defined by the presence of systolic blood pressure 140 mm Hg
nd/or diastolic blood pressure90 mmHg or receiving antihypertensive medication.
ypercholesterolemia was diagnosed when low-density lipoprotein cholesterol
as 130 mg/dl (3.4 mmol/l). Hypertriglyceridemia was defined when triglycerides
ere 150 mg/dl. Diabetes mellitus was defined by the presence of fasting plasma
lucose 126 mg/dl and/or hemoglobin A1c 6.4% or receiving oral antidiabetics.
Antihypertensives” and “oral diabetics” denote the numbers of patients receiving any
ntihypertensive and antidiabetic agents, respectively.
ACEI  angiotensin-converting enzyme inhibitors; ARB  angiotensin II type I
eceptor blockers.
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November 7, 2006:1825–31 Statin Reduces Plaque Inflammationlucose, hemoglobin A1c, and high-sensitivity C-reactive pro-
ein (hsCRP). They were measured at a commercial laboratory
SRL, Fukuoka, Japan).
tatistical analysis. Data are described as mean values 
D. Paired and unpaired t tests were performed for com-
arisons between the baseline and follow-up and between
he 2 groups, respectively. Pearson correlation coefficient
as used for correlation analysis. A value of p  0.05 was
onsidered to be statistically significant.
ESULTS
linical characteristics. The baseline demographic pro-
les were well matched between the statin and the diet
roups (Table 1). Their medications were not changed
uring the study. During the 3-month follow-up period,
here were no significant changes in clinical characteristics
igure 1. Representative transaxial images of 18F-fluorodeoxyglucose
omography (CT) (middle), and co-registration of PET and CT (PET/CT) (ri
f 2 patients.xcept lipid profiles (Table 2). Although simvastatin tended
o decrease hsCRP levels, the effect was inconsistent and did
ot reach the statistical significance.
8FDG-PET imaging. As shown in Figure 1, abnormal
ocal 18FDG uptakes were visualized in the transaxial
mages of the carotid arteries. Co-registration of PET and
T revealed that the 18FDG uptakes were located
ccentrically in the thickened arterial walls, suggesting
hat 18FDG uptakes reflect atherosclerotic plaque inflam-
ation. At baseline, a total of 117 and 123 inflammatory
laques were detected in the carotid arteries and the aorta of
he statin and diet groups, respectively. The SUVs of the
laques at baseline did not differ between the statin and the
iet groups.
After 3 months of treatment, simvastatin attenuated
8FDG uptakes in the atherosclerotic plaques, whereas
on emission tomography (FDG-PET) (left), enhanced computerized
18positr
ght) showing FDG uptakes in the carotid arterial plaques (arrowheads)
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Statin Reduces Plaque Inflammation November 7, 2006:1825–31ietary management alone did not (Fig. 2). Significant
hanges in the SUVs were observed only in the statin group
p  0.01) (Fig. 3A). Also, the magnitude of the SUV
hange was significantly greater in the statin group than in
he diet group (p  0.01) (Fig. 3B).
lasma lipids. At baseline, lipid profiles were similar
etween the statin and the control groups (Table 2).
fter 3 months of treatment, simvastatin reduced
DL-C by 30% (p  0.01) and increased HDL-C by
5% (p  0.01), whereas they were not changed in the
iet group (Table 2, Fig. 4). In the statin group, the
ecrease in the SUV was well correlated with the increase
n HDL-C level (p  0.01), whereas there was no such
orrelation for LDL-C (Fig. 5). In the diet group,
hanges in the SUVs had no correlation with alterations
n LDL-C or HDL-C.
igure 2. Effects of simvastatin on 18FDG uptake in atherosclerotic plaq
onths of treatment (post-treatment) with dietary management alone (di
ptakes (arrows) in the aortic arch and the carotid arteries. (Middle) 18F-fl
18
Table 2. Changes in Clinical Characteristics an
Diet Gro
Baseline
Body mass index, kg/m2 22.8  2.0
Systolic blood pressure, mm Hg 134  14
Pulse pressure, mm Hg 54  10
Glucose, mg/dl 106  14
Hemoglobin A1c, % 5.5  0.4
LDL cholesterol, mg/dl 140  27
HDL cholesterol, mg/dl 55  10
Triglycerides, mg/dl 141  68
hsCRP, mg/dl 0.09  0.11
Paired Student t test was performed for the comparison of
Difference between 2 groups was examined using unpaired St
HDL  high-density lipoprotein; hsCRP  high-sensithe co-registered images of FDG-PET and CT clearly show that the plaque
imvastatin. Abbreviations as in Figure 1.ISCUSSION
ecently, 18FDG-PET has emerged as a promising imaging
odality for visualizing plaque inflammation. Our prospec-
ive, controlled, randomized trial has shown here for the
rst time by the use of 18FDG-PET co-registered with
nhanced CT that 3-month simvastatin treatment attenu-
tes plaque inflammation. Although simvastatin decreased
DL-C and increased HDL-C, only the increase in
DL-C was correlated with the decrease in 18FDG uptake.
hus, the antiinflammatory effect of simvastatin on athero-
clerotic plaques may be one of the pleiotropic effects
ndependent of LDL-C-lowering.
Noninvasive identification of inflammatory plaque has
een challenging. With the recent advance in imaging
echnologies, we can get the morphology of plaques and
ome information about plaque stability (12,13) but cannot
flammation. Representative 18FDG-PET images at baseline and after 3
simvastatin. (Top) Dietary management alone had no effect on 18FDG
deoxyglucose uptakes were attenuated by simvastatin treatment. (Bottom)
18
asma Lipids
 22) Statin Group (n  21)
t-Treatment Baseline Post-Treatment
2.8  2.2 23.6  3.3 23.1  2.6
34  17 130  16 130  15
53  13 54  13 55  14
07  12 102  13 106  14
5.7  0.5 5.7  0.8 5.9  1.1
42  30 132  27 93  16*†
57  11 51  16 58  13*
32  67 156  94 134  75
.06  0.07 0.11  0.16 0.07  0.06
ta before and after treatment for a given treatment group.
t test. *p 0.01 versus baseline. †p 0.01 versus diet group.
-reactive protein; LDL  low-density lipoprotein.ue in
et) or
uorod Pl
up (n
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November 7, 2006:1825–31 Statin Reduces Plaque Inflammationee the inflammation directly. Because 18FDG-PET can
isualize tissue glucose metabolism with high sensitivity and
e can quantify 18FDG uptake in the region of interest, we
sed this metabolic imaging technique for the detection and
onitoring of plaque inflammation. Although PET has
imited spatial resolution, we showed that co-registration
ith CT can localize the 18FDG uptake to individual
therosclerotic vessel walls (Fig. 1). This is consistent with
revious studies showing that the co-registered 18FDG-
ET with CT (5,6) or high-resolution magnetic resonance
maging (MRI) (14) improved the accuracy of the diagnosis
f plaque inflammation. The 18FDG uptake has been
ttributed to infiltrating inflammatory cells (i.e., macro-
hages and lymphocytes) and subendothelial proliferation of
acrophages and smooth muscle cells within atherosclerotic
esions (3,15–17). In an experimental rabbit model, 18FDG
ccumulation corresponded to cellular infiltration in athero-
clerotic lesions (18). Furthermore, it has been shown that
8FDG is accumulated in the macrophage-rich area of the
laques, which were endoatherectomized from the PET-
ositive carotid lesions (6). These observations raised a
ossibility that serial 18FDG-PET imaging is capable of
urveying inflammatory activity within the plaque.
Blood pool activity may be a possible source of the
igure 3. Quantitative analysis of the effects of simvastatin on 18F-
uorodeoxyglucose uptake in atherosclerotic plaque inflammation. (A) For
uantitative analysis, the maximum standardized uptake values (SUVs)
ere evaluated in individual plaques and averaged for analysis of the results
f the subject-wise SUV at baseline and after 3-month treatment (post-
reatment). (B) Changes in plaque SUVs from baseline. Plaque SUVs were
ignificantly reduced by simvastatin, but not by dietary management alone
diet). SUV denotes the changes in the SUV after treatment. Bar 1 SD.ascular 18FDG accumulation. However, it was unlikely in
h
whe present study. First, the co-registered image with CT
learly demonstrated that the uptakes were located in the
essel wall (Fig. 1). Second, vascular 18FDG uptakes were
ot uniformly distributed along the course of the arteries
Fig. 2). In addition, nonvisualization of the large compan-
on veins of the 18FDG-labeled arteries was considered
urther indirect evidence against the blood pool hypothesis.
hus, it is unlikely that blood pooling activity is the major
ource of the vascular 18FDG accumulation seen in the
resent study. Taken together, it is likely that the arterial
8FDG uptakes are present in the vessel wall but not in
lood pooling.
For quantitative analysis, we evaluated serial changes in the
UV within the plaque. The SUV is a quantified parameter of
nflammation. So far, there has been no available information
egarding the SUV levels of atherosclerotic plaques. In the
resent study, the plaque SUV at baseline was 1.69  0.27
ranging from 1.20 to 2.36) (Fig. 3A). The observed SUV
evels were comparable to those seen in small gastric cancers
r small metastatic thyroid tumors (19,20). Moreover, a very
ecent study has shown that given the SUV cut-off point of
.30, 18FDG-PET co-registered with enhanced CT has a
ensitivity of 90.9% and a specificity of 88.8% for the
iagnosis of active vessel inflammation in patients with
ortitis syndrome (21). It was possible that high plasma
lucose impaired FDG uptake in diabetic patients. Al-
hough 7 diabetic subjects were included in the present
tudy, they were well controlled on dietary therapy with or
ithout antidiabetics. In the statin and diet groups, there
ere no differences in the baseline SUV and the magnitude
igure 4. Changes in low-density lipoprotein (LDL) cholesterol (A) and
igh-density lipoprotein (HDL) cholesterol (B) after 3-month treatment
ith dietary management alone (diet) or simvastatin.
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Statin Reduces Plaque Inflammation November 7, 2006:1825–31f the SUV changes between diabetic and nondiabetic
ubjects (data not shown), suggesting that the presence of
iabetes had no impact on the plaque FDG uptake in this
tudy. Taken together, it is indicated that the observed
8FDG uptake in the plaques indicates vessel inflammation.
n our study, the intra- and interobserver variability was
5%, and repeated studies with the 3-month interval gave
imilar SUVs in the diet group. Thus, the SUV measure-
ents had good reproducibility. Accordingly, the present
tudy has indicated that atherosclerosis is an inflammatory
rocess and that the individual plaque activities can be
uantified by 18FDG-PET in humans.
The most important finding of the present study is that
8FDG-PET metabolic imaging can clearly visualize anti-
nflammatory effects of simvastatin on the plaque (Fig. 2).
ecent studies using high-resolution MRI demonstrated
hat it took more than 12 months for simvastatin to regress
therosclerotic plaques (12,13). Thus, although we did not
xamine the morphologic changes in this study, it is likely
hat in spite of the attenuation of plaque inflammation, the
egression of the plaque might not have yet occurred in our
atients with 3 months of simvastatin treatment. The
bserved anti-inflammatory effect of simvastatin may be
elated to the reduction of inflammatory cell infiltration and
laque stabilization. Crisby et al. (22) have demonstrated
hat patients after 3-month statin treatment had less lipid
nd oxidized LDL-C and fewer macrophages and T cells in
he endatherectomized carotid samples compared with pa-
ients without statin. In the MIRACL (Myocardial Isch-
mia Reduction With Aggressive Cholesterol Lowering)
23) and PROVE-IT (Pravastatin or Atorvastatin Evalua-
igure 5. Correlations of changes in plaque 18F-fluorodeoxyglucose upta
holesterol (LDL, mg/dl) after 3-month treatment with dietary manage
HDL in the statin group. Abbreviations as in Figure 4.ion and Infection Therapy) (24) trials, significant benefits di.e., the decreased incidence of unstable angina) occurred
ithin the first month of treatment. Thus, our present study
ay support the hypothesis that the attenuation of plaque
nflammation, rather than the anatomic regression, plays a
ole in the mechanism underlying the early beneficial effects
f statins seen in clinical practice. In the present study, the
ffects of simvastatin on the serum CRP level, a systemic
nflammatory marker, were not significant. One possible
eason was the small size of the study. A second was the
ide variability of the hsCRP levels in the present study.
nother possibility is that the dose of simvastatin in this
tudy (5 to 20 mg/day) was too small to reduce the systemic
nflammatory marker. Future investigation with a larger
tudy size is necessary to address this issue.
There were several possible mechanisms whereby simva-
tatin attenuated plaque inflammation. Simvastatin treat-
ent reduced LDL-C by 30% (Table 2, Fig. 4). However,
he reduction in the SUV was not correlated with the extent
f LDL-C-lowering in the statin group (Fig. 5), suggesting
hat the LDL-C–dependent effect was the minor mecha-
ism of the observed benefits. The reduction in plaque
nflammation was correlated with the increase in HDL-C in
he statin group. Thus, the HDL-C increase may be
mportant in the mechanism of attenuation of plaque
nflammation by simvastatin. However, it is also possible
hat pleiotropic effects other than HDL-C–dependent
echanism mediate the antiinflammatory effect of simva-
tatin on the plaque.
tudy limitations. First, the small study size limits our
nterpretation and discussion. Second, longer drug admin-
stration and observation periods might provide us abun-
SUV) with alterations in HDL cholesterol (HDL, mg/dl) and LDL
alone (diet) or simvastatin. SUV had a significant correlation only withkes (antly clear evidence of the anti-inflammatory effects of
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November 7, 2006:1825–31 Statin Reduces Plaque Inflammationimvastatin on the plaque. Third, the control group should
ave received lipid-lowering drugs (i.e., resins) to reduce the
DL-C to the same level of the statin group. However, the
aseline LDL-C levels were not so high to warrant using other
ipid-lowering drugs other than statins. Thus, we created the
iet group as control. Next, several patients having aspirin and
ngiotensin II receptor blocker/angiotensin-converting en-
yme inhibitor were included in the present study. We do not
eny the possibility that anti-inflammatory properties of these
gents may have enhanced the effects of simvastatin on the
laques. Finally, a future prospective study with a larger
umber of patients is needed to address whether the 18FDG
ptake is a predictor of cardiovascular events. Future tech-
ical innovations (e.g., the development of macrophage-
pecific PET tracers) would provide more specific informa-
ion for detecting vulnerable plaques.
onclusions. 18F-fluorodeoxyglucose PET visualized in-
ammation of atherosclerotic plaques and that simvastatin
ttenuated it. The anti-inflammatory effect of simvastatin
n the plaques may be one of the pleiotropic effects
ndependent of LDL-C–lowering effects.
eprint requests and correspondence:Dr. Hisashi Kai, Department
f Medicine/Cardiovascular Research Institute, Division of Cardio-
ascular Medicine, Kurume University School of Medicine, 67
sahi-machi, Kurume 830-0011, Japan. E-mail: naikai@med.
urume-u.ac.jp.
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